Shijiazhuang Yiling Pharmaceutical Co Ltd
SZSE:002603

Watchlist Manager
Shijiazhuang Yiling Pharmaceutical Co Ltd Logo
Shijiazhuang Yiling Pharmaceutical Co Ltd
SZSE:002603
Watchlist
Price: 16.04 CNY -1.05% Market Closed
Market Cap: 26.8B CNY
Have any thoughts about
Shijiazhuang Yiling Pharmaceutical Co Ltd?
Write Note
Shijiazhuang Yiling Pharmaceutical Co Ltd
/
Balance Sheet
/
Additional Paid In Capital

Shijiazhuang Yiling Pharmaceutical Co Ltd
Additional Paid In Capital

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Shijiazhuang Yiling Pharmaceutical Co Ltd
Additional Paid In Capital Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Additional Paid In Capital CAGR 3Y CAGR 5Y CAGR 10Y
Shijiazhuang Yiling Pharmaceutical Co Ltd
SZSE:002603
Additional Paid In Capital
¥2.3B
CAGR 3-Years
0%
CAGR 5-Years
-5%
CAGR 10-Years
0%
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Additional Paid In Capital
¥14.1B
CAGR 3-Years
0%
CAGR 5-Years
61%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Additional Paid In Capital
¥1.1B
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
1%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Additional Paid In Capital
¥3.2B
CAGR 3-Years
-2%
CAGR 5-Years
14%
CAGR 10-Years
21%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Additional Paid In Capital
¥17.6B
CAGR 3-Years
-1%
CAGR 5-Years
0%
CAGR 10-Years
30%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Additional Paid In Capital
¥858.7m
CAGR 3-Years
294%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Shijiazhuang Yiling Pharmaceutical Co Ltd
Glance View

Market Cap
26.8B CNY
Industry
Pharmaceuticals

Shijiazhuang Yiling Pharmaceutical Co Ltd, rooted in the northern heart of China, embodies a harmonious blend of traditional Chinese medicine and modern pharmaceutical science. Born from the insightful vision of Wu Yiling, a prominent figure in integrating traditional Chinese medical practices with contemporary research methodologies, the company has grown into a significant player in the healthcare sector. Its foundation is deeply entrenched in leveraging ancient herbal wisdom while adopting cutting-edge biopharmaceutical technologies. At the core of its operations, Yiling Pharmaceutical specializes in the research, development, and production of therapeutic drugs aimed at treating chronic diseases and boosting immunity. This dual approach allows the company to carve out a niche in producing signature products like Lianhua Qingwen, a respiratory treatment renowned for its efficacy in alleviating symptoms from colds and flu. What powers Yiling Pharmaceutical's continued growth is its steadfast commitment to research and development, translated into a structured pipeline of innovative drugs. The company's funding funnel directs substantial resources into ongoing research, ensuring a constant expansion and refinement of their product portfolio. With an emphasis on effectiveness backed by rigorous scientific validation, Yiling has successfully navigated the complexities of pharmaceutical regulations, extending its reach beyond domestic borders to international markets. This expansionist strategy, coupled with a deep understanding of traditional medicine, forms a robust revenue stream, encapsulating both the domestic market's demand for traditional therapies and the international community's growing interest in alternative medicine solutions. Through these channels, Yiling harmonizes its traditional roots with a forward-thinking business model, ensuring steady financial footholds and promising horizons.

Intrinsic Value
19.51 CNY
Undervaluation 18%
Intrinsic Value
Price
What is Intrinsic Value?

See Also

What is Shijiazhuang Yiling Pharmaceutical Co Ltd's Additional Paid In Capital?
Additional Paid In Capital
2.3B CNY

Based on the financial report for Sep 30, 2024, Shijiazhuang Yiling Pharmaceutical Co Ltd's Additional Paid In Capital amounts to 2.3B CNY.

What is Shijiazhuang Yiling Pharmaceutical Co Ltd's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 10Y
0%

Over the last year, the Additional Paid In Capital growth was 0%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 210,800+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.